HCA Healthcare Inc.

ticker: HCA step: 01 generated: 2026-05-12 source: quick-research

HCA Healthcare, Inc. (HCA) — Business Overview

Business Description

HCA Healthcare is the largest for-profit healthcare provider in the United States — operates 190 hospitals + ~2,500 ambulatory sites of care (surgery centers, freestanding ERs, urgent care, physician clinics) in 19 states + United Kingdom. Captures ~5% of total US hospital admissions. Hub-and-spoke operating model links acute-care hospitals with outpatient centers to capture patients across the entire care continuum.

Revenue Model

~$75.6B FY2025 revenue from hospital-based services + outpatient services (now 42% of patient revenue). Payer mix FY2025: Managed Care + Private Insurance ~48%, Medicare ~32%, Medicaid ~10%, Self-Pay + International ~10%. Revenue per admission rises with patient acuity (case mix). Scale + payer-negotiation leverage = best-in-class economics among hospital systems.

Products & Services

• 190 Acute Care Hospitals — Cardiac, oncology, neurosciences, orthopedic, emergency, women's services
• ~125 Freestanding Outpatient Surgery Centers — Lower-cost surgical settings
• Freestanding ERs + Urgent Care Centers — Capture entry-point patient acquisition
• Physician Clinics — Primary + specialist physician network
• Sarah Cannon Cancer Network — Multi-state oncology platform
• HealthONE — Major Denver-area health system
• MD Now Urgent Care — Florida urgent care platform
• HCA International — UK operations (London Bridge Hospital, etc.)

Customer Base & Go-to-Market

~38M patient encounters annually. Concentrated in growth markets: Texas, Florida (largest), Tennessee, Virginia, Nevada, Colorado, Indiana. Geographic concentration in high-growth Sun Belt states + UK. Diversified payer mix protects from single-payer concentration risk.

Competitive Position

#1 US for-profit hospital operator by revenue + size. Competes with Tenet Healthcare (THC), Universal Health Services (UHS), Community Health Systems (CYH), HCA Florida vs nonprofits AdventHealth, Baptist, Memorial. Differentiation: scale + hub-and-spoke + data analytics + capital investment in growth corridors + acuity mix shift.

Key Facts

• Founded: 1968
• Headquarters: Nashville, TN
• Employees: ~280,000 (caregivers + physicians + staff)
• Exchange: NYSE (HCA)
• Sector / Industry: Healthcare / Healthcare Facilities (Hospitals)
• Market Cap: ~$110-120B
• CEO: Sam Hazen (since 2019)

ticker: HCA step: 04 generated: 2026-05-12 source: quick-research

HCA Healthcare, Inc. (HCA) — Financial Snapshot

Income Statement Summary

FY25: Same-facility admissions +2.4% in Q4; full-year inpatient + outpatient surgery + ER visits all positive. Adj EBITDA +12%; EBITDA margin 20.6% (record high). EPS +29% (driven by share buybacks compounding effect).

Cash Flow & Balance Sheet (FY2024)

Key Ratios (approximate)

• P/E: ~16x | EV/EBITDA: ~9-10x | FCF Yield: ~5.5%
• Revenue Growth (TTM): ~7% | Op Margin: ~15%
• Dividend Yield: ~1.0% | Modest dividend; capital return primarily via buybacks
• Aggressive buybacks: ~$8-10B annually = ~7-8% share count reduction

Growth Profile

Long-term: 5-7% revenue growth (admissions + price/acuity) + 100bps margin expansion + 10-12% adj EBITDA growth + 12-15% EPS growth (with aggressive buybacks). $5.2B capex plan adds 600-700 beds annually + ORs + ASCs. Hub-and-spoke + AI/analytics = $400M resiliency program savings.

Forward Estimates

• FY 2026: Revenue ~$80B; adj EBITDA $16-17B; adj EPS $29.10-31.50 (raised guidance)
• ACA + Medicaid headwind: $600-900M EBITDA hit (manageable)
• FY 2027: Adj EPS ~$33-36 with full-year 2026 buybacks compounding
• $10B buyback authorization (Jan 2026) for 2026-27 execution

ticker: HCA step: 12 generated: 2026-05-12 source: quick-research

HCA Healthcare, Inc. (HCA) — Investment Catalysts & Risks

Bull Case Drivers

1. Bullish 2026 guidance + $10B buyback authorization — HCA raised 2026 EPS guidance to $29.10-31.50 (above $29.46 analyst average), anchored to $400M cost-savings resiliency program (AI + analytics + shared services). Authorized $10B buyback (Jan 2026) = ~8% of market cap. Buyback compounding drives 12-15% EPS growth over base 5-7% revenue growth. 2025 EPS +29% YoY.

2. Volume + acuity tailwinds — record inpatient occupancy — Same-facility admissions +2.4% in Q4 2025 (+5.5% in 2024). Outpatient surgery + ER visits also growing. Inpatient occupancy at all-time high. HCA expanding capacity: 600-700 beds/year + new ORs + 125 ASCs. Hub-and-spoke model captures full continuum of patient care. Sun Belt geographic exposure (Texas, Florida) = demographic tailwind.

3. 20.6% EBITDA margin record + scale advantages — FY25 adj EBITDA margin reached record 20.6% (+90bps YoY). Scale advantages: bulk purchasing, payer negotiating power, data analytics + AI, shared services. Best-in-class hospital operator metrics vs Tenet, UHS, Community Health. Resiliency program: $400M cost savings program in 2026.

4. 190 hospitals + 2,500 ambulatory sites = irreplaceable footprint — Largest US for-profit hospital network + ambulatory presence. Captures ~5% of total US hospital admissions. Geographic concentration in growth Sun Belt states. Building new facilities is extraordinarily difficult (capital + regulatory + labor) = HCA's footprint is a multi-decade competitive moat.

Bear Case Risks

1. ACA exchange subsidies + Medicaid reform = $1B+ EBITDA hit — CFO Mike Hart guided $600-900M EBITDA hit in 2026 from health insurance exchange dynamics (premium tax credit expiration). Plus $250-450M net benefit decline from Medicaid state supplemental payment program changes. Combined could exceed $1B. Bear case $425 target assumes ACA breach + resiliency underdelivery + Florida grandfathering rejection.

2. Trump healthcare policy uncertainty (Medicaid expansion + ACA) — Trump 47 + GOP Congress could further reduce Medicaid + ACA funding in 2026-27. If federal Medicaid expansion repealed or capped, HCA payor mix deteriorates. Inflation Reduction Act drug pricing + 340B reforms also relevant. Hospital industry sees 2026 as a "make-or-break" year per Axios.

3. Inflation + tariff impact on medical supplies — Medical supplies + devices facing inflation. New 2026 tariff regime (Section 232 + reciprocal) could increase imported supply costs. HCA mitigating via supply base diversification + contract pricing, but ongoing margin pressure. Labor inflation also persistent.

4. Premium valuation + leveraged balance sheet — Net debt/EBITDA ~2.7x is elevated post buyback financing. P/E ~16x is below peers but not cheap given policy headwinds. Stock has gone -8.5% on policy news. Capital return capacity could compress if EBITDA disappoints.

Upcoming Events

• Q2 2026 earnings (July 2026) — ACA enrollment dynamics + resiliency program execution
• Q3 2026 earnings (October 2026) — Mid-year guide reset + CMS state program decisions
• CMS state Medicaid program decisions — Direct EBITDA impact
• Open Enrollment 2027 (Oct-Nov 2026) — Exchange volume signal
• AHA + hospital industry policy advocacy — Federal Medicaid reform outcomes

Analyst Sentiment

Sell-side consensus is Buy with 13 of 25 analysts rating Buy + 2 Outperform vs 9 Hold + 1 Sell. Mean price target $543 (15.1% upside from ~$472). Bulls cite scale moat + volume growth + 20.6% EBITDA margin + $10B buyback + Sun Belt demographics. Bears focus on ACA/Medicaid headwinds + Trump policy + tariff cost. HCA is widely viewed as the highest-quality public hospital operator with cyclical policy headwinds.

Research Date

Generated: 2026-05-12